|1.||Gründker, Carsten: 4 articles (01/2008 - 01/2002)|
|2.||Emons, Günter: 4 articles (01/2008 - 01/2002)|
|3.||Ramon y Cajal, Santiago: 3 articles (08/2013 - 10/2006)|
|4.||Bast, Robert C: 3 articles (01/2012 - 01/2006)|
|5.||Nicholson, Robert I: 3 articles (01/2012 - 07/2007)|
|6.||Esteva, Francisco J: 3 articles (02/2010 - 01/2003)|
|7.||van Diest, P J: 3 articles (10/2009 - 04/2001)|
|8.||Zhu, Zhenping: 3 articles (01/2009 - 03/2006)|
|9.||Günthert, Andreas R: 3 articles (01/2008 - 01/2002)|
|10.||Fu, Jian: 2 articles (09/2015 - 11/2005)|
04/01/2001 - "The study shows that clear cell tumors are able to up-regulate angiogenic growth factor receptors more efficiently than chromophil (papillary), that clear cell tumors can use pathways independent of VHL to regulate angiogenesis, and that this combined regulation may account for their more aggressive phenotype, which suggests that targeting VEGFR1 (flt-l) may be particularly effective in these tumor types."
01/01/2011 - "In conclusion, our in vitro study suggests that one contributing factor to the minor responses obtained with EGFR-directed therapy may be downregulation of this receptor in tumor cell aggregates, possibly resulting in acquisition of a more aggressive phenotype via other growth factor receptors like NTR1. "
06/05/2009 - "Here, we describe the potential of applying functional genomics and proteomics, taking the ERBB family of growth-factor receptors as an example to study the signaling network and its impact on cancer."
01/07/2008 - "Clinical trials indicate that growth factor receptors and their related signalling pathways play important roles in HCC cancer etiology and progression, thus providing rational targets for innovative cancer therapies. "
12/01/2005 - "Tumor biology studies have revealed a central role for growth factor receptors in tumor progression. "
|2.||Hepatocellular Carcinoma (Hepatoma)
01/07/2008 - "Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer."
09/01/2015 - "In conclusion, the data suggest that SF2 contributes to the elevated levels of ERK activation in hepatocellular carcinoma cells through modulating key component(s) downstream of growth factor receptors and upstream of ERK."
06/01/2011 - "Targeted therapies against insulinlike growth factor receptors may be justifiable in the treatment of hepatocellular carcinoma."
12/01/2007 - "Expression of oestrogen and growth factor receptors in hepatocellular carcinoma."
03/01/2014 - "Gene expression of growth factors and growth factor receptors for potential targeted therapy of canine hepatocellular carcinoma."
|3.||Prostatic Neoplasms (Prostate Cancer)
06/27/2003 - "Targeting intermediate cells by inhibition of their peptide growth factor receptors, therefore, offers novel treatment modalities for prostate cancer."
09/01/2013 - "Our results identify NTG as a novel agent for prostate cancer therapy with ability to inhibit Akt membrane localization and activity as well as the activation of growth factor receptors (GFRs), thereby efficiently synergizing with TRAIL exposure. "
03/01/2008 - "Because Vav3 may be chronically activated in prostate cancer by growth factor receptors, we examined the effects of a constitutively active (Ca) form of Vav3 on AR transcriptional activity. "
11/01/2006 - "During its biological progression, prostate cancer frequently develops dependence on growth factor receptors and their downstream signalling messengers, including c-Src. "
02/10/2005 - "Endocytosis of growth factor receptors, one of the mechanisms that controls growth factor signalling, was observed to be markedly changed in advanced metastatic prostate cancer. "
|4.||Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
04/01/2000 - "The expression of the type 1 growth factor receptors is significantly greater in the conjunctival epithelium of eyes with keratoconjunctivitis sicca than normal eyes. "
04/01/2000 - "To investigate the expression of type 1 growth factor receptors (epidermal growth factor receptor, ErbB2, and ErbB3) in the conjunctival epithelium of patients with keratoconjunctivitis sicca. "
|1.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|4.||Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
|7.||axitinib (AG 013736)
|9.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|10.||Epidermal Growth Factor Receptor (EGF Receptor)
|4.||Drug Therapy (Chemotherapy)